title: Progress in VZV vaccination? Some concerns.
abstract: Since 1995, many countries have been aiming to replace the natural immunity against varicella by a vaccine-induced immunity to protect against varicella and herpes zoster. While the frequency of varicella in childhood has been significantly reduced, in future, herpes zoster morbidity might increase in the elderly due to the weaker immunity post-vaccination and the absence of immunity boosting silent reinfections. In countries, where less than 90 % of children are covered by universal vaccination, varicella zoster virus (VZV) infection is not completely eradicated, but might move from childhood to the age of young adults who suffer from more serious complications. A special VZV vaccine against herpes zoster in adults aged >60 years has proven to be effective in many cases, but not all vaccinees. This might lead to problems regarding the acceptance of vaccination and delay rapid antiviral therapy to prevent the post-zosteric neuralgia. An efficacious-inactivated VZV vaccine to protect immunocompromised patients is still missing. VZV vaccines and vaccination strategies have to be optimised to avoid that the quality of life and cost savings from varicella reduction in childhood are offset by more VZV diseases in adults.
authors: Institute of Medical Virology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. H.W.Doerr@em.uni-frankfurt.de
authors: H W
authors: HW
authors: Doerr
mesh_terms: D000367:Age Factors; D006562:Herpes Zoster / Q000453:epidemiology* / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D014611:Vaccination / Q000379:methods* / Q000639:trends; D018140:Varicellovirus / Q000276:immunology*
chemical_list: D053061:Herpes Zoster Vaccine
references: Vaccine. 2013 Mar 25;31(13):1680-94
references: 22659447
references: Br Med Bull. 2012 Sep;103(1):115-27
references: 22859715
references: Med J Aust. 2008 Feb 4;188(3):171-6
references: 18241179
references: Vaccine. 2000 Jun 15;18(25):2775-8
references: 10812218
references: Clin Infect Dis. 2010 Jul 15;51(2):197-213
references: 20550454
references: Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858
references: 23076951
references: Vaccine. 2012 Feb 1;30(6):1225-34
references: 22119592
references: Curr Top Microbiol Immunol. 2010;342:v-vi
references: 20973159
references: Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006505
references: 21412895
references: Dtsch Med Wochenschr. 2001 Nov 16;126(46):1289-93
references: 11709730
references: Vaccine. 2001 Oct 12;20(1-2):121-4
references: 11567755